MTOR and epilepsy: Our data, as well as recent work correcting PI3K-dependent (53) or TSC2-dependent (54) epilepsies with more targeted drugs, imply that direct correction of a hyperactive node may be more effective than the simple use of rapalogs for all mTOR pathway disorders.